Tesamorelin vs Sermorelin: What the Research Shows

The short version

Tesamorelin vs sermorelin comes down to chain length and staying power. Both are based on GHRH, the brain's "make growth hormone" signal, and both work by telling the pituitary to release more of the body's own growth hormone rather than injecting it. The difference: tesamorelin is the full-length, 44-amino-acid version with a chemical guard that keeps an enzyme from breaking it down, while sermorelin is a shorter 29-amino-acid fragment. Tesamorelin also has the far larger clinical record — it is FDA-approved for one HIV use, where sermorelin has a different and older regulatory history.

Same target, different molecules

Tesamorelin and sermorelin are both GHRH-receptor agonists — secretagogues that prompt the pituitary to secrete the body's own growth hormone instead of supplying it directly ^[6][11]. Neither is a growth hormone; both work one step upstream, on the same receptor, raising GH and then IGF-1.

The structural difference is chain length. Tesamorelin is a synthetic analogue of the full-length human GHRH(1-44), carrying a trans-3-hexenoyl group on its N-terminus ^[4]. Sermorelin is GHRH(1-29) — the first 29 amino acids of the same hormone, the shortest fragment that retains full GH-releasing activity. Tesamorelin's full-length sequence plus its N-terminal modification are what give it resistance to DPP-IV, the enzyme that rapidly inactivates native GHRH ^[6].

Stability and pharmacokinetics

The trans-3-hexenoyl modification is tesamorelin's defining engineering feature: it blocks the DPP-IV cleavage that destroys native GHRH within minutes, extending plasma activity relative to the unmodified hormone ^[6]. Even so, tesamorelin's plasma half-life is short — on the order of 26-38 minutes per secondary sources, with an apparent clearance around 1,060 L/h in population PK modeling ^[11].

Sermorelin, as the truncated GHRH(1-29) without that N-terminal protection, is also rapidly cleared and is conventionally dosed for its short action. The practical distinction the tesamorelin literature establishes is that its IGF-1 effect persists across the day despite rapid plasma clearance, supporting once-daily dosing in the trials ^[11]. Detailed half-life data sit on the mechanism page.

Depth of the clinical record

The starkest difference is evidence. Tesamorelin carries an unusually deep clinical dataset for a GHRH-based compound: an FDA approval (NDA 022505, 2010) for HIV-associated lipodystrophy, two pivotal Phase 3 trials reducing visceral fat by 15.2% at 26 weeks and a sustained 18% at 52 weeks ^[1][2][5], a JAMA hepatic-fat trial ^[3], a healthy-men mechanistic study ^[4], and a 2026 meta-analysis of five randomized trials ^[15]. A narrative review framed tesamorelin's development specifically around the rationale that GHRH-analogue (GRF-analogue) approaches may be better tolerated than recombinant growth hormone ^[6].

Sermorelin's regulatory history is different and older, and it does not carry the same body of large modern visceral-fat RCTs. This site documents the tesamorelin record; it does not make efficacy claims for sermorelin beyond noting it is the truncated GHRH(1-29) secretagogue.

What the comparison does not establish

No head-to-head randomized trial in this literature directly compares tesamorelin and sermorelin on visceral fat, IGF-1, or any clinical endpoint. The comparison here is structural and pharmacological — full-length stabilized GHRH(1-44) versus truncated GHRH(1-29) — not a claim that one outperforms the other in a controlled setting.

Both remain subject to the same caveats that apply to any GHRH secretagogue: stimulating the GH axis raises IGF-1, a growth factor, and tesamorelin is FDA-approved only for HIV-associated lipodystrophy, with all other uses off-label ^[5]. Both are GHRH-class agents prohibited in sport under WADA category S2. The side effects and safety record for tesamorelin is on the research page.